Ophthotech Corp

Most Recent

  • uploads///NKTR
    Company & Industry Overviews

    Nektar’s Deals: Daiichi Sankyo, Ophthotech, Bristol-Myers Squibb

    Agreement with Daiichi Sankyo In May 2016, Nektar Therapeutics (NKTR) entered into a collaboration and licensing agreement with Daiichi Sankyo, under which Nektar granted exclusive commercialization rights for its product candidate, Onezeald, to Daiichi Sankyo in Europe. Onezeald is a long-acting topoisomerase-1 inhibitor in clinical development for treating adult patients with advanced breast cancer. Nektar […]

    By Kenneth Smith
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI on a Downward Slope, but How Steep?

    On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.